OBJECTIVE: To determine whether soluble interleukin 2 receptor (sIL-2R) levels correlate with natural history of disease in patients with systemic sclerosis (SSc). METHODS: The following groups were studied: Group I included 81 consecutive new patients with SSc. Group II consisted of 21 patients with diffuse cutaneous (dc) SSc whose peripheral blood and affected skin had been analyzed for T lymphocyte subsets. Group III contained 38 patients with dcSSc with serial sIL-2R determinations during the course of disease. sIL-2R was performed using a commercial double monoclonal antibody ELISA technique. RESULTS: The 81 Group I patients with SSc had a mean sIL-2R level of 821 units compared with 35 controls, who had a mean of 389 units (p < 0.001). sIL-2R level significantly correlated with the extent of skin thickening (p < 0.005). In Group II patients, sIL-2R was found to correlate with the CD4 to CD8 ratio. Blindly assessed clinical evidence of disease activity from the serial samples of 38 Group III patients was consistent with sIL-2R levels in 83% of the samples. There was high correlation of change in sIL-2R with change in skin score over time in Group III subjects (r = 0.71). CONCLUSIONS: These results suggest a role for T cell activation in the pathogenesis of SSc. sIL-2R levels may be useful adjunct to clinical evaluation in assessing disease activity and predicting future events in patients with SSc.
OBJECTIVE: To determine whether soluble interleukin 2 receptor (sIL-2R) levels correlate with natural history of disease in patients with systemic sclerosis (SSc). METHODS: The following groups were studied: Group I included 81 consecutive new patients with SSc. Group II consisted of 21 patients with diffuse cutaneous (dc) SSc whose peripheral blood and affected skin had been analyzed for T lymphocyte subsets. Group III contained 38 patients with dcSSc with serial sIL-2R determinations during the course of disease. sIL-2R was performed using a commercial double monoclonal antibody ELISA technique. RESULTS: The 81 Group I patients with SSc had a mean sIL-2R level of 821 units compared with 35 controls, who had a mean of 389 units (p < 0.001). sIL-2R level significantly correlated with the extent of skin thickening (p < 0.005). In Group II patients, sIL-2R was found to correlate with the CD4 to CD8 ratio. Blindly assessed clinical evidence of disease activity from the serial samples of 38 Group III patients was consistent with sIL-2R levels in 83% of the samples. There was high correlation of change in sIL-2R with change in skin score over time in Group III subjects (r = 0.71). CONCLUSIONS: These results suggest a role for T cell activation in the pathogenesis of SSc. sIL-2R levels may be useful adjunct to clinical evaluation in assessing disease activity and predicting future events in patients with SSc.
Authors: Xiang Guo; Brandon W Higgs; Anne C Bay-Jensen; Morten A Karsdal; Yihong Yao; Lorin K Roskos; Wendy I White Journal: J Invest Dermatol Date: 2015-05-20 Impact factor: 8.551
Authors: M Molteni; S Della Bella; B Mascagni; S Bazzi; C Zulian; S Compasso; M Lessi; R Scorza Journal: Clin Exp Immunol Date: 1999-04 Impact factor: 4.330
Authors: Kenneth J Warrington; Usha Nair; Laura D Carbone; Andrew H Kang; Arnold E Postlethwaite Journal: Arthritis Res Ther Date: 2006 Impact factor: 5.156